EA200801132A1 - Новые улучшенные композиции для лечения рака - Google Patents

Новые улучшенные композиции для лечения рака

Info

Publication number
EA200801132A1
EA200801132A1 EA200801132A EA200801132A EA200801132A1 EA 200801132 A1 EA200801132 A1 EA 200801132A1 EA 200801132 A EA200801132 A EA 200801132A EA 200801132 A EA200801132 A EA 200801132A EA 200801132 A1 EA200801132 A1 EA 200801132A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
methods
improved compositions
cancer treatment
new improved
Prior art date
Application number
EA200801132A
Other languages
English (en)
Other versions
EA015781B1 (ru
Inventor
Амарджит Сингх
Сарабджит Сингх
Аджай К. Гупта
Мангеш М. Кулкарни
Original Assignee
Панацея Биотек Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Панацея Биотек Лимитед filed Critical Панацея Биотек Лимитед
Publication of EA200801132A1 publication Critical patent/EA200801132A1/ru
Publication of EA015781B1 publication Critical patent/EA015781B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение направлено на новые и улучшенные композиции противораковых лекарственных средств, предпочтительно таксанов, таких как паклитаксел и доцетаксел, их производных и их аналогов, способы получения этих композиций, способы фракционирования частиц на диапазоны размеров частиц и способы лечения пациентов, больных раком, этими композициями, которые снижают побочные эффекты, вызванные химиотерапией, особенно снижают алопецию, вызванную химиотерапией. Представленная композиция практически не содержит свободных лекарственных средств.
EA200801132A 2005-10-21 2006-10-19 Композиции для лечения рака EA015781B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1327MU2005 2005-10-21
IN1081MU2006 2006-07-10
PCT/IN2006/000427 WO2007069272A2 (en) 2005-10-21 2006-10-19 Pharmaceutical composition comprising at least one anticancer drug and at least one polymer

Publications (2)

Publication Number Publication Date
EA200801132A1 true EA200801132A1 (ru) 2009-02-27
EA015781B1 EA015781B1 (ru) 2011-12-30

Family

ID=38163340

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801132A EA015781B1 (ru) 2005-10-21 2006-10-19 Композиции для лечения рака

Country Status (13)

Country Link
US (1) US20100166872A1 (ru)
EP (1) EP1962906A4 (ru)
JP (1) JP2009512682A (ru)
AR (1) AR058130A1 (ru)
AU (1) AU2006324872B2 (ru)
BR (1) BRPI0617663A2 (ru)
CA (1) CA2626016A1 (ru)
CR (1) CR9989A (ru)
EA (1) EA015781B1 (ru)
IL (1) IL190882A0 (ru)
MA (1) MA29946B1 (ru)
RS (1) RS20080167A (ru)
WO (1) WO2007069272A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2591819C2 (ru) * 2014-03-03 2016-07-20 Закрытое акционерное общество "СКАЙ ЛТД" Способ получения фолликулярного белкового препарата и препарат, полученный данным способом

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2231144T3 (pl) * 2007-12-24 2014-12-31 Sun Pharma Advanced Res Co Ltd Nanodyspersja
US8865223B2 (en) 2008-02-11 2014-10-21 Technion Research And Development Foundation Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
US20110045092A1 (en) * 2008-02-11 2011-02-24 Livney Yoav D Casein particles encapsulating therapeutically active agents and uses thereof
WO2009101612A2 (en) 2008-02-11 2009-08-20 Technion Research And Development Foundation Ltd. Beta-casein assemblies for enrichment of food and beverages and methods of preparation thereof
US8871276B2 (en) 2008-02-11 2014-10-28 Technion Research And Development Foundation Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
GB0818747D0 (en) 2008-10-13 2008-11-19 Univ Nottingham Biocompatible responsive materials
EP2266546A1 (en) 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Process for the preparation of colloidal systems for the delivery of active compounds
JP5627039B2 (ja) 2009-06-19 2014-11-19 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド 薬物のナノ分散体およびその調製のための方法
WO2011017835A1 (en) * 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
CA2774669C (en) * 2009-09-21 2017-12-19 Jw Pharmaceutical Corporation Oxaliplatin nanoparticles and method for preparing same
BR112012028037A2 (pt) 2010-05-03 2016-08-02 Teikoku Pharma Usa Inc formulação de pró-emulsão líquida de taxano não aquosa, métodos para administrar um taxano a um paciente e para fabricar uma formulação de pró-emulsão de taxano, composição de emulsão de taxano, e, kit
AU2011262308B2 (en) * 2010-06-01 2014-07-31 Geistlich Pharma Ag Methods and compositions for oral pharmaceutical therapy
WO2012058462A2 (en) * 2010-10-29 2012-05-03 Isis Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
US20120141551A1 (en) * 2010-12-02 2012-06-07 Ecosynthetix Ltd. Aptamer bioconjugate drug delivery device
PT2699233T (pt) 2011-04-20 2017-07-03 Univ Sydney Material particulado e toxina celular para utilização no tratamento de um tumor sólido
CN103635179B (zh) 2011-04-28 2017-12-29 普拉福姆五金器具第二有限公司 亲脂性药剂的改进的胃肠外制剂以及制备和使用其的方法
WO2013124867A1 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US10143700B2 (en) 2013-02-19 2018-12-04 Amrita Vishwa Vidyapeetham Nanoparticle formulations for delivering multiple therapeutic agents
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
SG11201601218PA (en) 2013-09-16 2016-04-28 Astrazeneca Ab Therapeutic polymeric nanoparticles and methods of making and using same
KR20150047336A (ko) 2013-10-24 2015-05-04 삼성전자주식회사 나노입자, 이를 제조하는 방법, 및 이의 용도
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN103739672B (zh) * 2013-12-31 2015-06-10 威特曼生物科技（南京）有限公司 一种聚乙二醇修饰的抑制vegfr2酪氨酸激酶多肽及其应用
CN107530373B (zh) 2015-02-01 2023-12-29 欧森尼克斯有限责任公司 用于在患者中口服施用的含有砷的高表面积冻干组合物
JP2018507227A (ja) 2015-03-03 2018-03-15 キュアポート インコーポレイテッド 二薬搭載リポソーム医薬製剤
EP3265059A4 (en) 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
CN106137969B (zh) 2015-04-03 2020-05-15 四川科伦药物研究院有限公司 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用
CN110753541A (zh) * 2017-04-24 2020-02-04 Zy治疗公司 用于体内递送的药物组合物、基本上不溶于水的药理学活性剂的制备方法
WO2019028457A2 (en) * 2017-08-04 2019-02-07 University Of Houston System FORMULATION OF NANOSUSPENSION OF DIETHYLSTILBESTROL INJECTABLE
CN111918675A (zh) 2018-03-28 2020-11-10 格林马克生物医药股份有限公司 磷酸盐交联淀粉纳米颗粒和牙科治疗
JP2021533194A (ja) 2018-07-31 2021-12-02 マイクロビオン コーポレーション ビスマス・チオール組成物及び創傷を治療する方法
FR3087650B1 (fr) * 2018-10-31 2021-01-29 Bio Even Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer
CN114767879A (zh) * 2022-06-02 2022-07-22 平顶山学院 一种多西紫杉醇恶性肿瘤靶向微球及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
AU6833994A (en) * 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
KR100904931B1 (ko) * 1997-06-27 2009-06-29 아브락시스 바이오사이언스, 엘엘씨 나노 입자 및 그의 제조 방법
WO2000071079A2 (en) * 1999-05-21 2000-11-30 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
CA2395132A1 (en) * 2000-01-05 2001-07-12 Imarx Therapeutics, Inc. Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
US7179484B2 (en) * 2002-11-06 2007-02-20 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
KR20140027554A (ko) * 2002-12-09 2014-03-06 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2591819C2 (ru) * 2014-03-03 2016-07-20 Закрытое акционерное общество "СКАЙ ЛТД" Способ получения фолликулярного белкового препарата и препарат, полученный данным способом

Also Published As

Publication number Publication date
IL190882A0 (en) 2008-11-03
AU2006324872A1 (en) 2007-06-21
BRPI0617663A2 (pt) 2011-08-02
CA2626016A1 (en) 2007-06-21
JP2009512682A (ja) 2009-03-26
CR9989A (es) 2008-07-18
EA015781B1 (ru) 2011-12-30
EP1962906A2 (en) 2008-09-03
EP1962906A4 (en) 2009-11-18
WO2007069272A3 (en) 2007-08-23
MA29946B1 (fr) 2008-11-03
AR058130A1 (es) 2008-01-23
RS20080167A (en) 2009-07-15
AU2006324872B2 (en) 2012-03-08
WO2007069272A2 (en) 2007-06-21
US20100166872A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
EA200801132A1 (ru) Новые улучшенные композиции для лечения рака
DE602006014579D1 (de) Heteroalkylgebundene pyrimidinderivate
MX2009009537A (es) Nanoparticula que comprende rapamicina y albumina como agente anticancer.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
SG10201906075VA (en) Methods of treating cancer
HK1131608A1 (en) Pyridinone compounds
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
EA201170161A1 (ru) 1,2,5-оксадиазолы в качестве ингибиторов индоламин-2,3-диоксигеназы
EA201270732A1 (ru) Антитела к csf-1r
ATE420117T1 (de) Kovalent an hyaluronsäure oder dessen derivate gebundene taxane
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
RU2012131663A (ru) Композиции и способы лечения рака яичников
EA201490132A1 (ru) Противовирусные соединения
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
EA200700601A1 (ru) Производные фениламинопиримидина как ингибиторы bcr-abl
MX2012007367A (es) Compuestos substituidos de imidazopiridinilo-aminopiridina.
WO2009120697A3 (en) Method and compositions for treatment of cancer
EA201000675A1 (ru) Производные хромана как модуляторы trpv3
EA201000141A1 (ru) Новые триазены для лечения рака
EA201071280A1 (ru) Производные хроманов как модуляторы trpv3
EA201391327A1 (ru) Терапевтическое лечение
LV15575A (lv) Selenofēnhromēnu deiterēti analogi, to iegūšana un izmantošana
TNSN08171A1 (en) Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
TH89330A (th) สารผสมที่ถูกปรับปรุงใหม่สำหรับการรักษามะเร็ง

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU